Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
CC transcript
PALATIN TECHNOLOGIES INC (PTN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
09/28/2023 8-K Quarterly results
08/10/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Initiates Clinical Program for Bremelanotide Co-Formulated with a PDE5i for the Treatment of ED in Patients Non-Responsive to PDE5i Treatment"
08/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Provides Update on VYLEESI® Collaborations · Licensee Fosun Pharma Reports First Commercial Sale in China o First prescription dispensed in Chinese Hainan Province · South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study o 93% of patients enrolled completed the Phase 3 trial in premenopausal patients with Hypoactive Sexual Desire Disorder o Data expected later this year o Supports submission to Korean Ministry of Food & Drug Safety for Marketing Approval CRANBURY, NJ – August 8, 2023 /PRNewswire/ – Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that Fosun Pharma, the licensee of Vyleesi in China, rep..."
08/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Announces Direct-to-Consumer Telehealth Partnership with UpScriptHealth™ for Vyleesi®"
08/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin to Participate in Canaccord Genuity’s 43rd Annual Growth Conference Cranbury, NJ, August 4, 2023 /PRNewswire/ – Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will participate at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023 at 5:00 p.m. ET in an Analyst led Fireside Chat. A live webcast of the Fireside Chat will be available on the Investors section of Palatin’s website at http://www.palatin.com . A replay of the webcast will be available for 30 days following the presentation. About Palatin Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that..."
07/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Announces Preliminary Fourth Quarter Fiscal 2023 Vyleesi ® Product Revenue Results"
05/16/2023 8-K Quarterly results
Docs: "Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update"
05/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023 CRANBURY, N.J., May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 16, 2023, at 11:00 a.m. ET. The conference call will include a review of the company’s operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q3 Fiscal Year 2023 Results Press Release 05/16/2023 at 7:30 a.m. ET Q3 Fiscal Year 2023 Conference Call-Live 05/16/2023 at 11:00 ..."
05/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader Webinar CRANBURY, N.J., May 8, 2023 /PRNewswire/ – Palatin Technologies, Inc. , a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today hosted a key opinion leader webinar presenting data from the Lead-In population of the ongoing PL9643 MELODY-1 Phase 3 clinical trial for Dry Eye Disease. The webinar was moderated by Carl Spana, Ph.D., President & CEO of Palatin, and featured Bruce C. Stouch, Ph.D. and George Ousler, M.S. and Michael B. Raizman, M.D., practicing ophthalmologist and CMO of Palatin. The data highlighted the excellent ocular tolerability of PL9643 eye drops and the broad efficacy on the...",
"Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference"
05/01/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
04/25/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
Docs: "Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update"
11/02/2022 8-K Quarterly results
09/22/2022 8-K Quarterly results
Docs: "Palatin Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update"
08/31/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Palatin Technologies, Inc., filed on August 29, 2022"
08/19/2022 8-K Quarterly results
06/28/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
02/15/2022 8-K Quarterly results
Docs: "Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update"
11/15/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update"
09/29/2021 8-K Quarterly results
Docs: "Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update ● Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 ● Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Currently Expected to Start Next Quarter with Top-Line Results Expected in the Second Half Calendar 2022 ● $60.1 Million in Cash and Cash Equivalents at June 30, 2021 – Projected Cash Runway Through Calendar 2022 ● Teleconference and Webcast today at 11:00 a.m. Eastern Time CRANBURY, NJ, September 29, 2021/PRNewswire/ -- Palatin Technologies, Inc., , a biopharmaceutical company developing first-in-class medicines ba..."
09/17/2021 8-K Quarterly results
08/06/2021 8-K Submission of Matters to a Vote of Security Holders
07/08/2021 8-K Quarterly results
06/10/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
03/12/2021 8-K Quarterly results
02/17/2021 8-K Quarterly results
12/18/2020 8-K Resignation/termination of a director
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy